Messenger RNA-Based Vaccines Against Infectious Diseases.
Clinical trials
Infectious diseases
LNP
SAM
Vaccines
mRNA
Journal
Current topics in microbiology and immunology
ISSN: 0070-217X
Titre abrégé: Curr Top Microbiol Immunol
Pays: Germany
ID NLM: 0110513
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
18
4
2020
medline:
6
1
2023
entrez:
18
4
2020
Statut:
ppublish
Résumé
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.
Substances chimiques
Vaccines, Synthetic
0
RNA, Messenger
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-145Informations de copyright
© 2020. Springer Nature Switzerland AG.
Références
Abrams MT et al (2010) Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 18:171–180. https://doi.org/10.1038/mt.2009.208
doi: 10.1038/mt.2009.208
pubmed: 19738601
Akinc A, Thomas M, Klibanov AM, Langer R (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7:657–663. https://doi.org/10.1002/jgm.696
doi: 10.1002/jgm.696
pubmed: 15543529
Alberer M et al (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390(10101):1511–1520. https://doi.org/10.1016/S0140-6736(17)31665-3
doi: 10.1016/S0140-6736(17)31665-3
pubmed: 28754494
Allard SD et al (2012) A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 142:252–268. https://doi.org/10.1016/j.clim.2011.10.010
doi: 10.1016/j.clim.2011.10.010
pubmed: 22177848
An Y et al (2013) Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms. J Proteome Res 12:3707–3720. https://doi.org/10.1021/pr400329k
doi: 10.1021/pr400329k
pubmed: 23848607
pmcid: 3800089
Andries O et al (2015) N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 217:337–344. https://doi.org/10.1016/j.jconrel.2015.08.051
doi: 10.1016/j.jconrel.2015.08.051
pubmed: 26342664
Asrani KH et al (2018) Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol 15:756–762. https://doi.org/10.1080/15476286.2018.1450054
Awasthi S et al (2019) Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 4(39):eaaw7083. https://doi.org/10.1126/sciimmunol.aaw7083
Bahl K et al (2017) Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 25:1316–1327. https://doi.org/10.1016/j.ymthe.2017.03.035
doi: 10.1016/j.ymthe.2017.03.035
pubmed: 28457665
pmcid: 5475249
Baiersdörfer M et al (2019) A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids 15:26–35. https://doi.org/10.1016/j.omtn.2019.02.018
doi: 10.1016/j.omtn.2019.02.018
pubmed: 30933724
pmcid: 6444222
Balazs DA, Godbey W (2011) Liposomes for use in gene delivery. J Drug Deliv 2011:326–497. https://doi.org/10.1155/2011/326497
doi: 10.1155/2011/326497
pubmed: 21490748
Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME (2013) New vaccines for neglected parasitic diseases and dengue. Transl Res 162:144–155. https://doi.org/10.1016/j.trsl.2013.03.006
doi: 10.1016/j.trsl.2013.03.006
pubmed: 23578479
Beeson J G et al (2019) Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med 11(474):eaau1458. https://doi.org/10.1126/scitranslmed.aau1458
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.3330
doi: 10.1038/nbt.3330
pubmed: 26348965
pmcid: 4978509
Bloom DE, Black S, Rappuoli R (2017) Emerging infectious diseases: a proactive approach. Proc Natl Acad Sci 114:4055–4059. https://doi.org/10.1073/pnas.1701410114
doi: 10.1073/pnas.1701410114
pubmed: 28396438
pmcid: 5402424
Bogers WM et al (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211:947–955. https://doi.org/10.1093/infdis/jiu522
doi: 10.1093/infdis/jiu522
pubmed: 25234719
Brazzoli M et al (2016) Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 90:332–344. https://doi.org/10.1128/JVI.01786-15
doi: 10.1128/JVI.01786-15
pubmed: 26468547
Brewer TF (2000) Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31(Suppl 3):S64–S67. https://doi.org/10.1086/314072
doi: 10.1086/314072
pubmed: 11010824
Brito LA et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22:2118–2129. https://doi.org/10.1038/mt.2014.133
doi: 10.1038/mt.2014.133
pubmed: 25027661
pmcid: 4429691
Bugeon S et al (2017) Direct and efficient transfection of mouse neural stem cells and mature neurons by in vivo mRNA electroporation. Development 144:3968–3977. https://doi.org/10.1242/dev.151381
doi: 10.1242/dev.151381
pubmed: 28982684
Chahal JS et al (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci 113:E4133–E4142. https://doi.org/10.1073/pnas.1600299113
doi: 10.1073/pnas.1600299113
pubmed: 27382155
pmcid: 4961123
Chahal JS et al (2017) An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep 7:252. https://doi.org/10.1038/s41598-017-00193-w
doi: 10.1038/s41598-017-00193-w
pubmed: 28325910
pmcid: 5427874
Conry RM et al (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397–1400
pubmed: 7882341
Cu Y et al (2013) Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 1:367–383. https://doi.org/10.3390/vaccines1030367
doi: 10.3390/vaccines1030367
pubmed: 26344119
pmcid: 4494232
Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25:1467–1475. https://doi.org/10.1016/j.ymthe.2017.03.013
doi: 10.1016/j.ymthe.2017.03.013
pubmed: 28412170
pmcid: 5498813
de Jong W et al (2019) iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials 20:361. https://doi.org/10.1186/s13063-019-3409-1
Demoulins T et al (2016) Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine 12:711–722. https://doi.org/10.1016/j.nano.2015.11.001
doi: 10.1016/j.nano.2015.11.001
pubmed: 26592962
Dezsi L et al (2014) Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 195:2–10. https://doi.org/10.1016/j.jconrel.2014.08.009
doi: 10.1016/j.jconrel.2014.08.009
pubmed: 25148822
Dowling W et al (2007) Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 81:1821–1837. https://doi.org/10.1128/JVI.02098-06
doi: 10.1128/JVI.02098-06
pubmed: 17151111
Duthie MS et al (2018) Heterologous immunization with defined RNA and subunit vaccines enhances T Cell responses that protect against Leishmania donovani. Front Immunol 9:2420. https://doi.org/10.3389/fimmu.2018.02420
doi: 10.3389/fimmu.2018.02420
pubmed: 30386348
pmcid: 6199377
Erasmus JH et al (2018) A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol Ther 26:2507–2522. https://doi.org/10.1016/j.ymthe.2018.07.010
doi: 10.1016/j.ymthe.2018.07.010
pubmed: 30078765
pmcid: 6171036
Feldman RA et al (2019) mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37:3326–3334. https://doi.org/10.1016/j.vaccine.2019.04.074
doi: 10.1016/j.vaccine.2019.04.074
pubmed: 31079849
Fotin-Mleczek M et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1–15. https://doi.org/10.1097/CJI.0b013e3181f7dbe8
doi: 10.1097/CJI.0b013e3181f7dbe8
pubmed: 21150709
Gandhi RT et al (2016) Immunization of HIV-1-Infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr 71:246–253. https://doi.org/10.1097/QAI.0000000000000852
doi: 10.1097/QAI.0000000000000852
pubmed: 26379068
pmcid: 4752409
Garcia AB et al (2018) Neutralization of the plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat Commun 9(1):1–13. https://doi.org/10.1038/s41467-018-05041-7
Gay CL et al (2018) Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AIDS Res Hum Retroviruses 34:111–122. https://doi.org/10.1089/aid.2017.0071
doi: 10.1089/aid.2017.0071
pubmed: 28636433
pmcid: 5771540
Gilleron J et al (2013) Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31:638–646. https://doi.org/10.1038/nbt.2612
doi: 10.1038/nbt.2612
pubmed: 23792630
Guardo AC et al (2017) Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). AIDS 31:321–332. https://doi.org/10.1097/QAD.0000000000001276
doi: 10.1097/QAD.0000000000001276
pubmed: 27677160
Hajj KA, Whitehead KA (2017) Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater 2(10):1–17. https://doi.org/10.1038/natrevmats.2017.56
doi: 10.1038/natrevmats.2017.56
Halasa NB, Gerber MA, Chen Q, Wright PF, Edwards KM (2008) Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 197:1448–1454. https://doi.org/10.1086/587643
doi: 10.1086/587643
pubmed: 18444800
Hassett KJ et al (2019) Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 15:1–11. https://doi.org/10.1016/j.omtn.2019.01.013
doi: 10.1016/j.omtn.2019.01.013
pubmed: 30785039
pmcid: 6383180
Hekele A et al (2013) Rapidly produced SAM
doi: 10.1038/emi.2013.54
pubmed: 26038486
pmcid: 3821287
Henao-Restrepo AM et al (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial. Lancet 389:505–518. https://doi.org/10.1016/S0140-6736(16)32621-6
doi: 10.1016/S0140-6736(16)32621-6
pubmed: 28017403
pmcid: 5364328
Henry C, Palm AE, Krammer F, Wilson PC (2018) From original antigenic sin to the universal influenza virus vaccine. Trends Immunol 39:70–79. https://doi.org/10.1016/j.it.2017.08.003
doi: 10.1016/j.it.2017.08.003
pubmed: 28867526
Hicks DJ, Fooks AR, Johnson N (2012) Developments in rabies vaccines. Clin Exp Immunol 169:199–204. https://doi.org/10.1111/j.1365-2249.2012.04592.x
doi: 10.1111/j.1365-2249.2012.04592.x
pubmed: 22861358
pmcid: 3444995
Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1–7. https://doi.org/10.1002/1521-4141(200001)30:1%3c1:AID-IMMU1%3e3.0.CO;2-%23
doi: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#
pubmed: 10602021
Hollevoet K, Declerck PJ (2017) State of play and clinical prospects of antibody gene transfer. J Transl Med 15:131. https://doi.org/10.1186/s12967-017-1234-4
doi: 10.1186/s12967-017-1234-4
pubmed: 28592330
pmcid: 5463339
Jacobson JM et al (2016) Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr 72:31–38. https://doi.org/10.1097/QAI.0000000000000926
doi: 10.1097/QAI.0000000000000926
pubmed: 26751016
pmcid: 4836975
Jagger BW et al (2019) Protective efficacy of nucleic acid vaccines against transmission of Zika virus during pregnancy in mice. J Infect Dis 220(10):1577–1588. https://doi.org/10.1093/infdis/jiz338
doi: 10.1093/infdis/jiz338
pubmed: 31260518
pmcid: 7137895
Joe PT et al (2019) Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J Transl Med 17:242. https://doi.org/10.1186/s12967-019-1991-3
doi: 10.1186/s12967-019-1991-3
pubmed: 31345237
pmcid: 6659201
Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7:e29732. https://doi.org/10.1371/journal.pone.0029732
doi: 10.1371/journal.pone.0029732
pubmed: 22238645
pmcid: 3251598
John S et al (2018) Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36:1689–1699. https://doi.org/10.1016/j.vaccine.2018.01.029
doi: 10.1016/j.vaccine.2018.01.029
pubmed: 29456015
Kallen K-J et al (2013) A novel, disruptive vaccination technology. Hum Vaccin Immunother 9:2263–2276. https://doi.org/10.4161/hv.25181
doi: 10.4161/hv.25181
pubmed: 23921513
pmcid: 3906413
Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967–977. https://doi.org/10.1038/nmat3765
doi: 10.1038/nmat3765
pubmed: 24150415
Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165–175. https://doi.org/10.1016/j.immuni.2005.06.008
doi: 10.1016/j.immuni.2005.06.008
pubmed: 16111635
Kariko K et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16:1833–1840. https://doi.org/10.1038/mt.2008.200
doi: 10.1038/mt.2008.200
pubmed: 18797453
Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39:e142. https://doi.org/10.1093/nar/gkr695
doi: 10.1093/nar/gkr695
pubmed: 21890902
pmcid: 3241667
Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, Vossen A, de Melker HE (2017) Congenital cytomegalovirus infection: child development, quality of life and impact on daily life. Pediatr Infect Dis J 36:1141–1147. https://doi.org/10.1097/INF.0000000000001663
doi: 10.1097/INF.0000000000001663
pubmed: 28650934
Kose N et al (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against Chikungunya infection. Sci Immunol 4(35):eaaw6647. https://doi.org/10.1126/sciimmunol.aaw6647
Kowalski PS, Rudra A, Miao L, Anderson DG (2019) Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther 27:710–728. https://doi.org/10.1016/j.ymthe.2019.02.012
doi: 10.1016/j.ymthe.2019.02.012
pubmed: 30846391
pmcid: 6453548
Kreiter S et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031–9040. https://doi.org/10.1158/0008-5472.CAN-10-0699
doi: 10.1158/0008-5472.CAN-10-0699
pubmed: 21045153
Kreiter S et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692–696. https://doi.org/10.1038/nature14426
doi: 10.1038/nature14426
pubmed: 25901682
pmcid: 4838069
Li M et al (2016) Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release 228:9–19. https://doi.org/10.1016/j.jconrel.2016.02.043
doi: 10.1016/j.jconrel.2016.02.043
pubmed: 26941035
Li B, Zhang X, Dong Y (2019) Nanoscale platforms for messenger RNA delivery. Wiley Interdisc Rev Nanomed Nanobiotechnol 11(2):e1530
Lindgren G et al (2017) Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 8:1539. https://doi.org/10.3389/fimmu.2017.01539
doi: 10.3389/fimmu.2017.01539
pubmed: 29181005
pmcid: 5693886
Liu MA (2019) A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines 7:37. https://doi.org/10.3390/vaccines7020037
doi: 10.3390/vaccines7020037
pubmed: 31022829
pmcid: 6631684
Looker KJ, Garnett GP, Schmid GP (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805–812, A. https://doi.org/10.2471/blt.07.046128
Lorenzi JC et al (2010) Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol 10:77. https://doi.org/10.1186/1472-6750-10-77
doi: 10.1186/1472-6750-10-77
pubmed: 20961459
pmcid: 2972232
Luo F et al (2017) Induction of protective immunity against toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP). Front Microbiol 8:605. https://doi.org/10.3389/fmicb.2017.00605
doi: 10.3389/fmicb.2017.00605
pubmed: 28424680
pmcid: 5380742
Lutz J et al (2017) Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2:29. https://doi.org/10.1038/s41541-017-0032-6
doi: 10.1038/s41541-017-0032-6
pubmed: 29263884
pmcid: 5648897
Martens TF, Remaut K, Demeester J, De Smedt SC, Braeckmans K (2014) Intracellular delivery of nanomaterials: how to catch endosomal escape in the act. Nano Today 9:344–364. https://doi.org/10.1016/j.nantod.2014.04.011
doi: 10.1016/j.nantod.2014.04.011
Martinon F et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719–1722. https://doi.org/10.1002/eji.1830230749
doi: 10.1002/eji.1830230749
pubmed: 8325342
Maruggi G et al (2017) Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35:361–368. https://doi.org/10.1016/j.vaccine.2016.11.040
doi: 10.1016/j.vaccine.2016.11.040
pubmed: 27939014
Maruggi G, Zhang C, Li J, Ulmer JB, Yu D (2019) mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 27:757–772. https://doi.org/10.1016/j.ymthe.2019.01.020
doi: 10.1016/j.ymthe.2019.01.020
pubmed: 30803823
pmcid: 6453507
Maugeri M et al (2019) Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun 10:4333. https://doi.org/10.1038/s41467-019-12275-6
doi: 10.1038/s41467-019-12275-6
pubmed: 31551417
pmcid: 6760118
Melo M et al (2019) Immunogenicity of RNA replicons encoding HIV env immunogens designed for self-assembly into nanoparticles. Mol Ther 27:2080–2090. https://doi.org/10.1016/j.ymthe.2019.08.007
doi: 10.1016/j.ymthe.2019.08.007
pubmed: 31515132
pmcid: 6904793
Meyer M et al (2018) Modified vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis 217:451–455. https://doi.org/10.1093/infdis/jix592
doi: 10.1093/infdis/jix592
pubmed: 29281112
Meyer M, Malherbe DC, Bukreyev A (2019) Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol 27:8–16. https://doi.org/10.1016/j.tim.2018.08.008
doi: 10.1016/j.tim.2018.08.008
pubmed: 30201511
Mohamed M et al (2019) PEGylated liposomes: immunological responses. Sci Technol Adv Mater 20:710–724. https://doi.org/10.1080/14686996.2019.1627174
doi: 10.1080/14686996.2019.1627174
pubmed: 31275462
pmcid: 6598536
Mooi FR, de Greeff SC (2007) The case for maternal vaccination against pertussis. Lancet Infect Dis 7:614–624. https://doi.org/10.1016/S1473-3099(07)70113-5
doi: 10.1016/S1473-3099(07)70113-5
pubmed: 17537674
Moyo N et al (2019) Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol Ther Methods Clin Dev 12:32–46. https://doi.org/10.1016/j.omtm.2018.10.010
doi: 10.1016/j.omtm.2018.10.010
pubmed: 30547051
Paessler S, Weaver SC (2009) Vaccines for Venezuelan equine encephalitis. Vaccine 27(Suppl 4):D80–D85. https://doi.org/10.1016/j.vaccine.2009.07.095
doi: 10.1016/j.vaccine.2009.07.095
pubmed: 19837294
Pardi N et al (2017a) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543:248–251. https://doi.org/10.1038/nature21428
doi: 10.1038/nature21428
pubmed: 28151488
pmcid: 5344708
Pardi N et al (2017b) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8:14630. https://doi.org/10.1038/ncomms14630
doi: 10.1038/ncomms14630
pubmed: 28251988
pmcid: 5337964
Pardi N, Hogan MJ, Porter FW, Weissman D (2018a) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17:261–279. https://doi.org/10.1038/nrd.2017.243
doi: 10.1038/nrd.2017.243
pubmed: 29326426
pmcid: 5906799
Pardi N et al (2018b) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9:3361. https://doi.org/10.1038/s41467-018-05482-0
doi: 10.1038/s41467-018-05482-0
pubmed: 30135514
pmcid: 6105651
Pardi N et al (2018c) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571–1588. https://doi.org/10.1084/jem.20171450
doi: 10.1084/jem.20171450
pubmed: 29739835
pmcid: 5987916
Pardi N et al (2019) Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and Rhesus Macaques. Mol Ther Nucleic Acids 15:36–47. https://doi.org/10.1016/j.omtn.2019.03.003
doi: 10.1016/j.omtn.2019.03.003
pubmed: 30974332
pmcid: 6454128
Patel S et al (2017) Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Lett 17:5711–5718. https://doi.org/10.1021/acs.nanolett.7b02664
doi: 10.1021/acs.nanolett.7b02664
pubmed: 28836442
pmcid: 5623340
Pepini T et al (2017) Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol 198(10):4012–4024. https://doi.org/10.4049/jimmunol.1601877
doi: 10.4049/jimmunol.1601877
pubmed: 28416600
pmcid: 5421303
Petsch B et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210–1216. https://doi.org/10.1038/nbt.2436
doi: 10.1038/nbt.2436
pubmed: 23159882
Plotkin SA, Plotkin SL (2011) The development of vaccines: how the past led to the future. Nat Rev Microbiol 9:889–893. https://doi.org/10.1038/nrmicro2668
doi: 10.1038/nrmicro2668
pubmed: 21963800
Pollard C et al (2013) Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21:251–259. https://doi.org/10.1038/mt.2012.202
doi: 10.1038/mt.2012.202
pubmed: 23011030
Quiroz E, Moreno N, Peralta PH, Tesh RB (1988) A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 39:312–314. https://doi.org/10.4269/ajtmh.1988.39.312
doi: 10.4269/ajtmh.1988.39.312
pubmed: 2845825
Rappuoli R, Bottomley MJ, D’Oro U, Finco O, Gregorio ED (2016) Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med 213:469–481. https://doi.org/10.1084/jem.20151960
Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R (2017) RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol Biol 89–107
Rauch S, Jasny E, Schmidt KE, Petsch B (2018) New vaccine technologies to combat outbreak situations. Front Immunol 9:1963. https://doi.org/10.3389/fimmu.2018.01963
Rehman Z, Zuhorn IS, Hoekstra D (2013) How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J Control Release 166:46–56. https://doi.org/10.1016/j.jconrel.2012.12.014
doi: 10.1016/j.jconrel.2012.12.014
pubmed: 23266451
Richner JM et al (2017a) Modified mRNA vaccines protect against Zika virus infection. Cell 168:1114–1125 e1110. https://doi.org/10.1016/j.cell.2017.02.017
Richner JM et al (2017b) Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170:273–283 e212. https://doi.org/10.1016/j.cell.2017.06.040
Richner JM, Diamond MS (2018) Zika virus vaccines: immune response, current status, and future challenges. Curr Opin Immunol 53:130–136. https://doi.org/10.1016/j.coi.2018.04.024
doi: 10.1016/j.coi.2018.04.024
pubmed: 29753210
pmcid: 6141315
Roth C et al (2019) A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice. Front Immunol 10:1424. https://doi.org/10.3389/fimmu.2019.01424
doi: 10.3389/fimmu.2019.01424
pubmed: 31293584
pmcid: 6598640
Routy JP et al (2010) Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134:140–147. https://doi.org/10.1016/j.clim.2009.09.009
doi: 10.1016/j.clim.2009.09.009
pubmed: 19889582
Saadatnia G, Golkar M (2012) A review on human toxoplasmosis. Scand J Infect Dis 44:805–814. https://doi.org/10.3109/00365548.2012.693197
doi: 10.3109/00365548.2012.693197
pubmed: 22831461
Sabnis S et al (2018) A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther 26:1509–1519. https://doi.org/10.1016/j.ymthe.2018.03.010
doi: 10.1016/j.ymthe.2018.03.010
pubmed: 29653760
pmcid: 5986714
Sahay G, Alakhova DY, Kabanov AV (2010) Endocytosis of nanomedicines. J Control Release 145:182–195. https://doi.org/10.1016/j.jconrel.2010.01.036
doi: 10.1016/j.jconrel.2010.01.036
pubmed: 20226220
pmcid: 2902597
Sahay G et al (2013) Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31:653–658. https://doi.org/10.1038/nbt.2614
doi: 10.1038/nbt.2614
pubmed: 23792629
pmcid: 3814166
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 13:759–780. https://doi.org/10.1038/nrd4278
doi: 10.1038/nrd4278
pubmed: 25233993
Samsa MM et al (2019) Self-amplifying RNA vaccines for Venezuelan equine Encephalitis virus induce robust protective immunogenicity in mice. Mol Ther 27:850–865. https://doi.org/10.1016/j.ymthe.2018.12.013
doi: 10.1016/j.ymthe.2018.12.013
pubmed: 30770173
pmcid: 6453513
Scheel B et al (2004) Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 34:537–547. https://doi.org/10.1002/eji.200324198
doi: 10.1002/eji.200324198
pubmed: 14768059
Scheel B et al (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557–1566. https://doi.org/10.1002/eji.200425656
doi: 10.1002/eji.200425656
pubmed: 15832293
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319–1330. https://doi.org/10.4161/rna.22269
doi: 10.4161/rna.22269
pubmed: 23064118
pmcid: 3597572
Schnee M et al (2016) An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis 10:e0004746. https://doi.org/10.1371/journal.pntd.0004746
doi: 10.1371/journal.pntd.0004746
pubmed: 27336830
pmcid: 4918980
Schroeder J, Aebischer T (2011) Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin 7(Suppl):10–15. https://doi.org/10.4161/hv.7.0.14556
doi: 10.4161/hv.7.0.14556
pubmed: 21245661
Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9–21. https://doi.org/10.1111/j.1365-2796.2009.02189.x
doi: 10.1111/j.1365-2796.2009.02189.x
pubmed: 20059641
pmcid: 5308083
Scorza FB, Pardi N (2018) New kids on the block: RNA-based influenza virus vaccines. Vaccines (Basel) 6. https://doi.org/10.3390/vaccines6020020
Semple SC, Chonn A, Cullis PR (1998) Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Del Rev 32:3–17. https://doi.org/10.1016/S0169-409X(97)00128-2
doi: 10.1016/S0169-409X(97)00128-2
Semple SC et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172–176. https://doi.org/10.1038/nbt.1602
doi: 10.1038/nbt.1602
pubmed: 20081866
Settembre EC, Dormitzer PR, Rappuoli R (2014) Bringing influenza vaccines into the 21st century. Hum Vaccin Immunother 10:600–604. https://doi.org/10.4161/hv.27600
doi: 10.4161/hv.27600
pubmed: 24378716
Sohn RL et al (2001) In-vivo particle mediated delivery of mRNA to mammalian tissues: ballistic and biologic effects. Wound Repair Regen 9:287–296. https://doi.org/10.1046/j.1524-475X.2001.00287.x
doi: 10.1046/j.1524-475X.2001.00287.x
pubmed: 11679137
Steitz J, Britten CM, Wolfel T, Tuting T (2006) Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 55:246–253. https://doi.org/10.1007/s00262-005-0042-5
Stitz L et al (2017) A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis 11:e0006108. https://doi.org/10.1371/journal.pntd.0006108
doi: 10.1371/journal.pntd.0006108
pubmed: 29216187
pmcid: 5737050
Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216:106–121. https://doi.org/10.1016/j.tox.2005.07.023
doi: 10.1016/j.tox.2005.07.023
pubmed: 16140450
Szebeni J (2014) Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61:163–173. https://doi.org/10.1016/j.molimm.2014.06.038
doi: 10.1016/j.molimm.2014.06.038
pubmed: 25124145
Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA (2018) Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotech 13:1100–1108. https://doi.org/10.1038/s41565-018-0273-1
doi: 10.1038/s41565-018-0273-1
Tabernero J et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406–417. https://doi.org/10.1158/2159-8290.CD-12-0429
doi: 10.1158/2159-8290.CD-12-0429
pubmed: 23358650
Takahashi H, Sinoda K, Hatta I (1996) Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine. Biochim Biophys Acta 1289:209–216. https://doi.org/10.1016/0304-4165(95)00170-0
doi: 10.1016/0304-4165(95)00170-0
pubmed: 8600975
Tao W et al (2011) Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol Ther 19:567–575. https://doi.org/10.1038/mt.2010.282
doi: 10.1038/mt.2010.282
pubmed: 21179008
Taranejoo S, Liu J, Verma P, Hourigan K (2015) A review of the developments of characteristics of PEI derivatives for gene delivery applications. J Appl Polym Sci 132. https://doi.org/10.1002/app.42096
Telford JL (2008) Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3:408–416. https://doi.org/10.1016/j.chom.2008.05.004
doi: 10.1016/j.chom.2008.05.004
pubmed: 18541217
Thess A et al (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23:1456–1464. https://doi.org/10.1038/mt.2015.103
doi: 10.1038/mt.2015.103
pubmed: 26050989
pmcid: 4817881
Thran M et al (2017) mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med 9(10):1434–1447. https://doi.org/10.15252/emmm.201707678
doi: 10.15252/emmm.201707678
pubmed: 28794134
pmcid: 5623855
Tiwari PM et al (2018) Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun 9:3999. https://doi.org/10.1038/s41467-018-06508-3
doi: 10.1038/s41467-018-06508-3
pubmed: 30275522
pmcid: 6167369
Vaidyanathan S et al (2018) Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids 12:530–542. https://doi.org/10.1016/j.omtn.2018.06.010
doi: 10.1016/j.omtn.2018.06.010
pubmed: 30195789
pmcid: 6076213
Van Gulck E et al (2012) mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 26:F1–12. https://doi.org/10.1097/QAD.0b013e32834f33e8
doi: 10.1097/QAD.0b013e32834f33e8
pubmed: 22156965
Van Lint S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72:1661–1671. https://doi.org/10.1158/0008-5472.CAN-11-2957
doi: 10.1158/0008-5472.CAN-11-2957
pubmed: 22337996
Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9:265–274. https://doi.org/10.4161/hv.22661
doi: 10.4161/hv.22661
pubmed: 23291946
pmcid: 3859745
VanBlargan LA et al (2019) An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell Rep 25:3382–3392 e3383. https://doi.org/10.1016/j.celrep.2018.11.082
Vermeulen LMP et al (2018) Endosomal size and membrane leakiness influence proton sponge-based rupture of endosomal vesicles. ACS Nano 12:2332–2345. https://doi.org/10.1021/acsnano.7b07583
doi: 10.1021/acsnano.7b07583
pubmed: 29505236
Voysey M et al (2017) The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis. JAMA Pediatr 171:637–646. https://doi.org/10.1001/jamapediatrics.2017.0638
doi: 10.1001/jamapediatrics.2017.0638
pubmed: 28505244
pmcid: 5710349
Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45–52
doi: 10.1086/338231
pubmed: 11756980
Walker LM et al (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470. https://doi.org/10.1038/nature10373
doi: 10.1038/nature10373
pubmed: 21849977
pmcid: 3393110
Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC (2004) Venezuelan equine encephalitis. Annu Rev Entomol 49:141–174. https://doi.org/10.1146/annurev.ento.49.061802.123422
doi: 10.1146/annurev.ento.49.061802.123422
pubmed: 14651460
Wei X et al (2003) Antibody neutralization and escape by HIV-1. Nature 422:307–312. https://doi.org/10.1038/nature01470
doi: 10.1038/nature01470
pubmed: 12646921
Willis E et al (2020) Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci Transl Med 12:eaav5701. https://doi.org/10.1126/scitranslmed.aav5701
Wittrup A et al (2015) Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol 33:870–876. https://doi.org/10.1038/nbt.3298
doi: 10.1038/nbt.3298
pubmed: 26192320
pmcid: 4663660
Wolff JA et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
doi: 10.1126/science.1690918
pubmed: 1690918
Wu NC et al (2017) A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 13:e1006682. https://doi.org/10.1371/journal.ppat.1006682
doi: 10.1371/journal.ppat.1006682
pubmed: 29059230
pmcid: 5667890
Yates NL et al (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6:228ra239. https://doi.org/10.1126/scitranslmed.3007730
Yin H et al (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15:541–555. https://doi.org/10.1038/nrg3763
doi: 10.1038/nrg3763
pubmed: 25022906
Yin H, Kauffman KJ, Anderson DG (2017) Delivery technologies for genome editing. Nat Rev Drug Discov 16:387–399. https://doi.org/10.1038/nrd.2016.280
doi: 10.1038/nrd.2016.280
pubmed: 28337020
Younger DS, Younger AP, Guttmacher S (2016) Childhood vaccination: implications for global and domestic public health. Neurol Clin 34:1035–1047. https://doi.org/10.1016/j.ncl.2016.05.004
doi: 10.1016/j.ncl.2016.05.004
pubmed: 27719987
Zhao M, Li M, Zhang Z, Gong T, Sun X (2016) Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv 23:2596–2607. https://doi.org/10.3109/10717544.2015.1038856
doi: 10.3109/10717544.2015.1038856
pubmed: 26024387
Zhong Z et al (2019) Immunogenicity and protection efficacy of a naked self-replicating Zika virus vaccine. Vaccines (Basel) 7. https://doi.org/10.3390/vaccines7030096
Zost SJ et al (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci 114:12578–12583. https://doi.org/10.1073/pnas.1712377114
doi: 10.1073/pnas.1712377114
pubmed: 29109276
pmcid: 5703309